A therosclerosis is a chronic inflammatory disease causing progressive lesion formation and luminal narrowing of arteries. The underlying pathology is initiated by endothelial dysfunction and structural alterations after an imbalanced lipid metabolism and trapping of low-density lipoprotein (LDL) particles in the intima of arteries.
A therosclerosis is a chronic inflammatory disease causing progressive lesion formation and luminal narrowing of arteries. The underlying pathology is initiated by endothelial dysfunction and structural alterations after an imbalanced lipid metabolism and trapping of low-density lipoprotein (LDL) particles in the intima of arteries. 1, 2 Subsequently, intimal lipid accumulation triggers the release of various chemokines by activated endothelial cells, inducing a multiphase cascade of leukocyte infiltration and inflammatory responses in the arterial walls. As the knowledge of these inflammatory pathways has been growing during the past years, it has also uncovered new druggable targets that could complement the current treatment options, which do not directly interfere with the central inflammatory mechanisms driving atheroprogression. One endogenous pathway that has gained increasing attention for its wide-ranging and potent actions in suppressing maladaptive inflammatory responses is the melanocortin system consisting of melanocortin peptides and their cellular receptors. 3, 4 However, the role of melanocortin signaling and its promise as a therapeutic target in atherosclerosis remain fully unexplored.
Melanocortins are a family of peptides that are proteolytically cleaved from the common precursor molecule pro-opiomelanocortin. These peptides include melanocyte-stimulating hormones (α-, β-, and γ-MSH) and adrenocorticotropic hormone. They regulate important physiological functions by acting via G-protein-coupled melanocortin receptors (MC-Rs), named from MC1-R to MC5-R. 5, 6 Our recent findings indicate that α-MSH serves as a protective regulator in the vasculature by enhancing endothelium-dependent control of blood vessel tone. 7 Mechanistically, α-MSH was shown to augment vascular nitric oxide (NO) availability by activating MC1-R in the endothelium. Besides promoting endothelial function, mounting evidence indicates that α-MSH, through the activation of MC1-R and MC3-R, elicits potent tissue-protective and antiinflammatory effects in rodents in vivo, as well as in experimental in vitro models based on human cells and samples. This evidence is derived from observations in MC1-R and MC3-R knockout mouse models that exhibit increased levels of proinflammatory cytokines in injured tissues, rendering the mice susceptible to inflammatory diseases such as experimental colitis. 8, 9 Conversely, selective MC1-R and MC3-R agonists exert anti-inflammatory actions and put in motion proresolving processes. [10] [11] [12] [13] Recent data also indicate that MC1-R activation in an inflamed vasculature can inhibit cell adhesion and migration by acting on the adherent leukocytes and reduce the levels of a variety of chemokines, which are known to contribute to the pathogenesis of atherosclerosis. However, these findings have been exclusively derived from acute experiments such as vascular and cardiac ischemia/reperfusion models, whereas the potential of MC1-R and MC3-R activation in chronic inflammatory conditions such as atherosclerosis remains unexplored. Given that melanocortins and consequent signaling through the MC1-R and MC3-R seem to exert not only anti-inflammatory actions but also to promote vascular endothelial function, we anticipate that pharmacological targeting of MC1-R and MC3-R might beneficially modulate several atherogenetic processes and thus hold promise as a novel therapeutic strategy for atherosclerosis.
In the present study, we tested the hypothesis that pharmacological activation of MC-Rs ameliorates vascular dysfunction and inflammation in murine atherosclerosis. We investigated high-fat diet-fed LDL receptor-deficient mice expressing only apolipoprotein B100 (LDLR −/− ApoB 100/100 ), which represents a well-established model of atherosclerosis with lipid profile resembling human familial hypercholesterolemia. 14, 15 The mice were treated with low doses of the cyclic α-MSH analog melanotan II (MT-II), which has better in vivo stability and longer duration of action compared with the endogenous α-MSH. 16 Here, we focused on measuring fluorine-18-labeled glucose analog, fluorodeoxyglucose ( 18 F-FDG), uptake within the vasculature as a surrogate marker for vascular inflammation and evaluated the treatment effect of MT-II in this regard. Detection of 18 F-FDG accumulation in atherosclerotic plaques has proven to be a useful approach to evaluate the therapeutic effects of novel drugs on plaque inflammation before observable changes in plaque size. 17 LDLR −/− ApoB 100/100 mice were previously shown to develop atheromatous plaques with high macrophage density and consistent elevations in the plaque uptake of 18 F-FDG already after 2 months on an atherogenic diet, 18 representing a sensitive model to investigate novel experimental therapies and their modifying actions on 18 F-FDG uptake in the inflamed vasculature. Furthermore, the therapeutic potential of MT-II was assessed in terms of its ability to halt the progression of vascular dysfunction in atherosclerotic mice. Figure I in the online-only Data Supplement) and treated for the past 4 weeks by daily intraperitoneal injection of vehicle or MT-II (0.3 mg/kg). Because the melanocortin system has well-established roles in the regulation of energy and glucose metabolism, we carefully investigated whether chronic MT-II administration alters body weight, body composition, or glucose metabolism in atherosclerotic mice, thereby possibly biasing the analysis of 18 F-FDG uptake and distribution in aortic tissue. With the selected dose and dosage regimen, MT-II treatment had no effect on body weight of male or female mice in either of the age groups ( Figure II 
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MT-II Reduces the Uptake of 18 F-FDG in Atherosclerotic Plaques
Male LDLR −/− ApoB 100/100 mice developed prominent atherosclerotic plaques with a marked increase in the plaque burden in the older age group ( Figure 1A and 1B) . Female mice showed even more extensive plaque formation over time (0.51±0.03 mm 2 in female versus 0.36±0.04 mm 2 in male mice; P<0.01; Figure V in the online-only Data Supplement). However, in terms of plaque size, no significant treatment effect was noted for MT-II.
To determine atherosclerotic plaque inflammation, we injected mice with the radioactive glucose analog 18 F-FDG after a 4-hour fast and analyzed its uptake in the whole aorta and atherosclerotic plaques by biodistribution and autoradiography analyses, respectively. Blood glucose values, measured right before the injection of 18 F-FDG, were comparable between the vehicle-and MT-II-treated mice ( Figure VI in the online-only Data Supplement). The biodistribution results from male and female mice are shown in the Table and Table I in the online-only Data Supplement, respectively. Interestingly, MT-II treatment reduced the uptake of 18 F-FDG in the aorta of male mice ( Figure 1C) . A similar treatment effect of MT-II was also noted in the lymph nodes of 6-month-old male mice (Table) . As an indication that there was no general alteration F-FDG accumulation in other tissues such as the liver, skeletal muscle, and blood was comparable between the treatment groups.
Consistent with the reduced uptake of 18 F-FDG in the whole aorta, autoradiographic analysis showed that 18 F-FDG radioactivity was lower in atherosclerotic plaques of MT-II-treated male mice compared with vehicle-treated mice ( Figure 1D ), whereas no difference between treatment groups was noted in the uptake level of 18 F-FDG in nonatherosclerotic arterial walls ( Figure 1E ). Accordingly, the ratio of 18 F-FDG uptake between atherosclerotic plaques and nonatherosclerotic arterial walls was also reduced by MT-II treatment ( Figure 1F ). In support of these findings, the 18 F-FDG uptake in atherosclerotic plaques and the ratio of radioactivity distribution were similarly reduced in MT-II-treated female mice ( Figure VII in the online-only Data Supplement). In general, the level of 18 F-FDG uptake was higher in female mice compared with age-matched male mice, reflecting most likely higher insulin sensitivity of female mice (Table I in the online-only Data Supplement).
MT-II Treatment Induces a Shift Toward M2-Polarized Macrophage Phenotype in Atherosclerotic Plaques
Plaque macrophage count was analyzed by quantifying the area of macrophage 3 antigen (Mac-3)-positive cells in the intima of aortic sinuses ( Figure 2A ). The absolute macrophage-positive area was higher in 6-month-old compared with 4-month-old mice ( Figure 2B ), whereas macrophage density normalized to the intimal area was comparable between the age groups because of different-sized intimal areas (26±3% of F-FDG uptake and the possible modifying effect of MT-II on this correlation, atherosclerotic plaques in aortic longitudinal sections were categorized according to the extent of macrophage infiltration and matched with 18 F-FDG radioactivity values. We observed a significant correlation between the macrophage density and 18 F-FDG uptake ( Figure 2D ). Interestingly, this correlation was modified by MT-II treatment, which was able to reduce 18 F-FDG uptake specifically in macrophage-rich plaques. We then sought to investigate whether macrophage phenotype is altered in MT-II-treated mice. The expression of inducible NO synthase, a marker of the proinflammatory M1 phenotype, was virtually unaltered in MT-II-treated mice ( Figure 3B ). However, MT-II intervention significantly (P=0.01 for treatment effect) increased the expression of the anti-inflammatory M2 marker mannose receptor (mannose receptor C type 1), resulting in lower inducible NO synthase/mannose receptor C type 1 ratio particularly in older mice ( Figure 2C and 2D) . We determined the plasma levels of proinflammatory cytokines and chemokines further, which are known to contribute to the pathogenetic processes of atherosclerosis. We found ageassociated increases in the concentrations of interleukin-6 and chemokine (C-C motif) ligand 5 (CCL5) and similar trends also in interleukin-1β and tumor necrosis factor α levels in male mice (Figure VIII in the online-only Data Supplement). MT-II treatment seemed to reduce the levels of interleukin-1β and tumor necrosis factor α, but these effects did not reach statistical significance (P=0.09 and 0.12 for treatment effects, respectively) because of high interindividual variation. Nevertheless, chronic MT-II administration was able to significantly attenuate the increase of interleukin-6 in the older mice. In contrast, MT-II had no effect on CCL5 level or even an opposing effect, if anything. Collectively, these data indicate that MT-II intervention induced a shift from M1 to M2 cytokine expression without changing total macrophage content of the lesions, suggesting an increase in the proportion of M2-polarized macrophages in atherosclerotic plaques.
MT-II-Treated Mice Show Enhancement of Endothelium-Dependent and EndotheliumIndependent Relaxations in the Aorta
To evaluate vascular function in MT-II-treated mice, isolated rings of the aorta were first studied for contractile responses to phenylephrine. Vehicle-treated male mice showed augmentation of phenylephrine-evoked contraction with advanced age, and this effect was markedly blunted by MT-II treatment ( Figure 4A and 4B) . Contrary to the functional characteristics of the aorta in males, female mice displayed low contractile response to phenylephrine even after longer diet exposure, reflecting maintained ability of the aorta to resist vasoconstrictor influences ( Figure IX in the online-only Data Supplement). We also examined the sensitivity of the vascular smooth muscle layer to endothelium-independent relaxation evoked by the NO donor sodium nitroprusside ( Figure 4C and 4D) . Six-monthold vehicle-treated male mice showed impaired responses to sodium nitroprusside compared with younger male mice (log EC 50 ; −8.20±0.07 versus −8.75±0.06; P<0.05). MT-II treatment prevented this impairment of endothelium-independent relaxation. Female mice showed consistent responses to sodium nitroprusside with no detectable impairment in the response of older mice ( Figure IX in the online-only Data Supplement). Nevertheless, aortic sensitization to sodium nitroprussideevoked vasodilatation was observed in MT-II-treated mice at 4 months of age. Next, we monitored endothelium-dependent relaxation to acetylcholine. It was of note that MT-II treatment improved vasodilatory responses to acetylcholine in both age groups of male mice, an effect that was more prominent in 6-month-old mice ( Figure 5A 
Discussion
The present study aimed at investigating the therapeutic benefits of MC-R activation in pre-established atherosclerosis. To this end, we primarily evaluated the treatment effect of the subtype-nonselective MC-R agonist MT-II on atherosclerotic plaque inflammation by determining 18 F-FDG uptake. Here, we demonstrate that treatment with MT-II attenuates vascular inflammation and dysfunction in atherosclerotic LDLR −/− ApoB 100/100 mice. In parallel, this study consolidates the evidence that the detection of 18 F-FDG accumulation in atherosclerotic plaques serves as a sensitive tool to evaluate the anti-inflammatory efficacy of novel disease-modifying therapies before changes in plaque burden can be observed.
Uptake of 18 F-FDG in atherosclerotic plaques has been used as an indicator of inflammation and linked to increased glucose disposal by activated macrophages. [19] [20] [21] [22] Clinical studies using positron emission tomographic imaging have shown that established therapies of atherosclerosis such as statins produce subtle but yet clinically significant reductions in 
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18 F-FDG uptake in atherosclerotic lesions. [23] [24] [25] Thus, the evaluation of 18 F-FDG signal may be a useful approach to noninvasively monitor plaque inflammation and the effectiveness of therapies intended to alleviate inflammation in atherosclerosis. This method has successfully been adopted to murine atherosclerosis models, 18, 26 although certain limitations still exist in terms of its feasibility for in vivo positron emission tomographic imaging. 27 Therefore, we focused on investigating the effects of MT-II on 18 F-FDG uptake by ex vivo analyses. Considering that the uptake of the glucose analog 18 F-FDG is competitively affected by blood glucose concentration, we wanted to carefully characterize the metabolic phenotype of MT-II-treated mice and rule out the possibility that differences in glucose homeostasis are biasing the analysis of 18 F-FDG uptake. This was further justified by several lines of evidence indicating that the melanocortin system has the ability to modulate blood glucose levels and to improve insulin sensitivity predominantly via central MC4-R signaling. [28] [29] [30] However, based on a series of analyses on metabolic parameters, we found no signs of treatment effect on glucose handling or plasma cholesterol levels in this atherosclerotic mouse model. Importantly, the blood glucose levels before the injection of 18 F-FDG were comparable between the treatment groups, allowing reliable interpretation of the 18 F-FDG results. Without attenuating atherosclerotic lesion size or lesional macrophage accumulation, chronic MT-II administration was effective in reducing the 18 F-FDG uptake by atherosclerotic plaques, indicating an anti-inflammatory effect. Accumulation of 18 F-FDG into atherosclerotic lesions was shown to associate with macrophage content. MT-II-treated mice showed a similar association profile, but the 18 F-FDG uptake was exclusively blunted in macrophage-rich plaques. We then investigated macrophage phenotype because recent evidence demonstrates that 18 F-FDG uptake is primarily augmented in M1-polarized macrophages expressing proinflammatory markers such as inducible NO synthase, interleukin-1β, and interleukin-6, whereas the uptake is reduced by macrophage M2 polarization. 31 We found that resident macrophages in the lesions of MT-II-treated mice were polarized toward the anti-inflammatory M2 phenotype, thus providing a possible mechanistic explanation for the F-FDG uptake. These findings are supported by other studies proving that pharmacological targeting of MC-Rs suppresses the secretion of proinflammatory mediators by macrophages and induces M2 polarization in experimental models of inflammatory disease. 10, 32, 33 Consistent with the finding of decreased 18 F-FDG signal and altered macrophage phenotype, we demonstrate that the systemic inflammation profile was favorably modified in MT-II-treated mice. Specifically, MT-II treatment was able suppress the plasma levels of interleukin-1β and interleukin-6, which are considered as proinflammatory mediators promoting atherosclerosis. [34] [35] [36] Recent research by others, demonstrating anti-inflammatory potential of melanocortin peptides, 4, 10, 11 corroborates our findings and a suggestion that melanocortin activation could also attenuate the chronic inflammation associated with atherosclerosis. Using a variety of approaches from acute in vitro models to chronic administration under in vivo settings, α-MSH and synthetic MC-R agonists have been shown to reduce cytokine release by macrophages, with a preferential effect on interleukin-6 release, and to inhibit leukocyte trafficking in the inflamed vasculature. 10, 11 These anti-inflammatory actions are strongly linked to MC1-R and MC3-R signaling and the ability of these receptors to inhibit the activation of the nuclear transcription factor nuclear factor-κB, 3, 37, 38 which governs the expression of numerous cytokines, cytokine receptors, chemokines, and adhesion molecules. Furthermore, the expression of MC1-R and MC3-R is widespread in the cells of the immune system, including macrophages, B and T lymphocytes, dendritic cells, and endothelial cells. 3 Thus, the underlying mechanisms for the observed therapeutic effects of MT-II are likely to be multifactorial, involving 2 MC-R subtypes and a variety of different mediators after their activation. The present study validates the anti-inflammatory effects of melanocortins and the consequent therapeutic efficacy in atherosclerosis, but further research will be fundamental to explore the involved molecular-level mechanisms of these effects.
Our study also reveals that MC-R activation protects against the development of vascular dysfunction during prolonged exposure to atherogenic diet. Particularly, vasoconstrictor responsiveness was augmented, and endothelium-independent relaxations were impaired in older vehicle-treated male mice, indicating that the progression of vascular dysfunction occurs also during later stages of the disease. This was associated with age-related increases in the levels of inflammation markers, which might, at least in part, drive the gradual deterioration of vascular function. Importantly and well in line with our previous findings, 7 MT-II treatment translated into therapeutic effects in terms of both endothelium-dependent and endothelium-independent vasodilation. The former of these effects is attributable to endothelial MC1-R signaling and consequent enhancement of NO bioavailability as previously demonstrated. Given that endothelium-derived NO exerts a number vasoprotective effects beyond its direct vasodilatory properties, 39 it is conceivable that the augmentation of NO release after MT-II administration could contribute to the reduction of atherosclerotic plaque inflammation as measured by 18 F-FDG uptake. Taken together, the present results demonstrate that chronic MT-II treatment has wide-ranging effects in promoting vascular function of atherosclerotic mice.
Regarding the pharmacological aspects of the present study approach, a cyclic analog of α-MSH, MT-II, was used and given as a daily injection at a dose level of 0.3 mg/kg. This synthetic peptide possesses better resistance to enzymatic degradation compared with α-MSH, which prolongs its biological half-life and duration of action. 16, 40 It also binds with high affinity to both MC1 and MC3 receptors, probably resulting in synergistic effects on inflammatory burden. However, MT-II is known to elevate blood pressure and heart rate via central MC4-R activation and consequent sympathoexcitation, 41 which poses a significant adverse effect particularly in atherosclerosis that is often associated with hypertension. With the selected dosage regimen, we observed significant treatment effects on aortic 18 F-FDG uptake and function, but no effect on plaque burden. However, it remains to be determined whether modified timing and dosing of the MT-II therapy could halt the development of atheromatous plaques or even lead to regression of existing plaques. By targeting the pharmacological intervention at an earlier phase of the disease and for longer duration, it could beneficially balance the immune response during critical phases of plaque progression and thereby lead to an improved treatment outcome also in terms of lesion size and extent. Clearly, new agonists with more selective binding at the MC1-R and MC3-R and a more favorable pharmacokinetic profile need to be tested to explore fully the antiatherosclerotic potential of this class of compounds.
In conclusion, the present results demonstrate that the antiinflammatory and vasoactive effects of melanocortins could be therapeutically expanded to chronic inflammatory diseases such as atherosclerosis. Pharmacological targeting of MC-Rs was able to prevent the development of vascular dysfunction and attenuate plaque inflammation in pre-established atherosclerosis. These results provide the first evidence that MC-R agonists could have beneficial effects on atherosclerosis, but future studies will be instrumental to clarify their mechanisms and to evaluate the clinical potential of this treatment strategy. 
